Fermín Ignacio Milagro Yoldi-rekin lankidetzan egindako argitalpenak (8)

2024

  1. Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessment

    Journal of Physiology and Biochemistry

  2. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial

    Clinical Nutrition, Vol. 43, Núm. 7, pp. 1770-1781

2023

  1. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

2022

  1. A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers

    Panminerva medica, Vol. 64, Núm. 4, pp. 485-496

2021

  1. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study

    European Journal of Nutrition, Vol. 60, Núm. 6, pp. 3043-3057

  2. Three different genetic risk scores based on fatty liver index, magnetic resonance imaging and lipidomic for a nutrigenetic personalized management of nafld: The fatty liver in obesity study

    Diagnostics, Vol. 11, Núm. 6

2020

  1. Association of the SH2B1 RS7359397 gene polymorphism with steatosis severity in subjects with obesity and non-alcoholic fatty liver disease

    Nutrients, Vol. 12, Núm. 5

2019

  1. Association between sleep disturbances and liver status in obese subjects with nonalcoholic fatty liver disease: A comparison with healthy controls

    Nutrients, Vol. 11, Núm. 2